CME review article

The role of vitamin D in asthma
Manbir S. Sandhu, MD,* and Thomas B. Casale, MD**

Objective: To review the current literature on vitamin D and asthma, discussing the possible roles of vitamin D on asthma pathogenesis and the potential consequences of vitamin D deficiency.

Data Sources: PubMed database was searched from 1950 to 2009. Keywords used included asthma, vitamin D, inflammation, airway smooth muscle and cytokines.

Study Selection: Articles were selected based on relevance to the subject.

Results: Vitamin D deficiency has been associated with epidemiologic patterns observed in the asthma epidemic. Vitamin D deficiency is more common with obesity, African American ethnicity, and westernization of countries with higher-risk populations for asthma. Evidence suggests that vitamin D deficiency is associated with increased airway hyperresponsiveness, lower pulmonary functions, worse asthma control, and possibly steroid resistance. Lung epithelial cells express high baseline levels of 1α-hydroxylase. This allows the conversion of inactive calcidiol to active calcitriol locally within the lung. Calcitriol has been shown to inhibit the synthesis and release of certain cytokines, such as RANTES, platelet-derived growth factor, and matrix metalloproteinases, from bronchial smooth muscle cells, thereby leading to decreased lung inflammation and smooth muscle cell proliferation. Vitamin D also increases synthesis of interleukin 10 by CD4+CD25+Foxp3+ T-regulatory cells and dendritic cells, while concurrently inhibiting dendritic cell activation by downregulating expression of costimulatory molecules CD40 and CD80/86. Vitamin D is also capable of inducing the expression of several anti-infective molecules, such as cathelicidin. Thus, vitamin D has a number of biologic effects that are likely important in regulating key mechanisms in asthma.

Conclusions: We hypothesize that vitamin D supplementation may lead to improved asthma control by inhibiting the influx of inflammatory cytokines in the lung and increasing the secretion of interleukin 10 by T-regulatory cells and dendritic cells.


Off-label disclosure: Drs Sandhu and Casale have indicated that this article does not include the discussion of unapproved/investigative use of a commercial product/device.

Financial disclosure: Drs Sandhu and Casale have indicated that in the last 12 months they have not had any financial relationship, affiliation, or arrangement with any corporate sponsors or commercial entities that provide financial support, education grants, honoraria, or research support or involvement as a consultant, speaker’s bureau member, or major stock shareholder whose products are prominently featured either in this article or with the groups who provide general financial support for this CME program.

Instructions for CME credit
1. Read the CME review article in this issue carefully and complete the activity by answering the self-assessment examination questions on the form on page 192.
2. To receive CME credit, complete the entire form and submit it to the ACAAI office within 1 year after receipt of this issue of the Annals.

INTRODUCTION
Asthma is a considerable public health issue, with more than 300 million people affected worldwide. It remains the most common chronic disease of childhood in the world. In most cases, asthma has its onset in early childhood, with 80% to 90% of cases diagnosed in patients before the age of 6 years. The prevalence of asthma is greatest in westernized, industrialized nations, with a predilection toward countries farther away from the equator. In the United States, the lifetime prevalence of asthma is approximately 11.6 per 100 persons. The most recent data from 2006 indicate that close to 23 million Americans have asthma. More than 50% of these individuals had an asthma attack in 2006. In addition to the high morbidity of asthma, approximately 4,000 lives are lost per year. The economic cost of asthma is close to $20 billion annually. Asthma ranked in the top 10 prevalent conditions causing limitations of activity. Recent studies indicate that current pharmacotherapy is often inadequate in effectively
treated patients with asthma. In the Gaining Optimal Asthma Control study, only approximately 50% of patients had well-controlled asthma despite recommended treatment with an inhaled corticosteroid and a long-acting \( \beta \)-agonist. These data suggest a need for efforts to identify causes of the asthma epidemic and treatments aimed at the identified risk factors.

Evidence suggests there may be a cause-and-effect relationship with vitamin D deficiency and the increased incidence of asthma because vitamin D deficiency is associated with increased airway hyperresponsiveness, lower pulmonary functions, worse asthma control, and possibly steroid resistance. Indeed, vitamin D deficiency has been associated with epidemiologic patterns observed in the asthma epidemic. For example, vitamin D deficiency is more common with obesity, African American ethnicity, and westernization of countries reflecting higher-risk populations for asthma.

A limited number of studies have looked at pulmonary function parameters of asthma and chronic obstructive pulmonary disease and their relationship to vitamin D. In the late 1970s, Utz et al published a small randomized, double-blind, placebo-controlled study looking at the effects of oral calcium and vitamin D supplementation on pulmonary function. They found that compared with the placebo group, the active treatment group had statistically significant increases in forced expiratory volume in 1 second (FEV\(_1\)). Black and colleagues examined the relationship between serum vitamin D levels and lung function in a cross-sectional analysis of data from the Third National Health, Nutrition and Examination Survey (NHANES). This survey was conducted from 1988 to 1994 and included 14,091 people who had undergone spirometry and measurements of serum 25-hydroxy vitamin D (25(OH)D\(_3\)) levels. The serum 25(OH)D\(_3\) concentration was inversely related to body mass index. It was lower in non-Hispanic blacks and Mexican Americans and participants who smoked more than 20 cigarettes per day. They examined the relationship between percentage of predicted FEV\(_1\) and forced vital capacity (FVC) values and the circulating concentration of 25(OH)D3. After adjustment for confounders, the mean FEV\(_1\) was 126 mL (SE, 22 mL) and the mean FVC was 172 mL (SE, 26 mL) greater for the highest quintile of serum 25(OH)D3 level (>85.7 nmol/L) compared with the lowest quintile (<40.4 nmol/L; \( P < .0001 \)). Thus, it appears as though there is a relationship between serum concentrations of 25(OH)D3 and FEV\(_1\) and FVC.

In a recent study published in the *American Journal of Respiratory and Critical Care Medicine*, 28% of children living in Costa Rica had vitamin D deficiency. This was an interesting observation given the prevalence of sunlight; however, darker skin pigmentation contributes to low cutaneous production of vitamin D. These investigators also examined the relationship between serum 25(OH)D3 levels and asthma and allergic diseases. They found that higher serum 25(OH)D3 levels were significantly and inversely associated with total IgE levels and peripheral blood eosinophil counts. A higher serum 25(OH)D3 level was also associated with reduced odds of any hospitalization in the previous year, lower use of anti-inflammatory medications for asthma, and less airway hyperresponsiveness. A 10-ng/mL increase in serum 25(OH)D3 was associated with a decrease of 25 IU/mL in total IgE and of 29/mm\(^3\) in eosinophils in peripheral blood. Higher serum 25(OH)D3 levels were also associated with reductions in antigen specific IgE and skin test size.

An important question is what mechanism does vitamin D use to exert its biologic effects on airway inflammation, remodeling and hyperresponsiveness, and thereby asthma control. The answer to this question will invariably be complicated given the wide-ranging effects of vitamin D on airway epithelium, bronchial smooth muscle, and immune cells central to the pathogenesis of asthma (Table 1). This article reviews the current literature on vitamin D and asthma, discussing the possible roles of vitamin D on asthma pathogenesis and the potential consequences of vitamin D deficiency. We searched PubMed from 1950 to 2009 with keywords asthma, vitamin D, inflammation, airway smooth muscle, cytokines and selected articles based on relevance to the subject.

### VITAMIN D OVERVIEW

The first step in the biosynthesis of vitamin D involves UV light from the sun. Seven-dehydrocholesterol is distributed in the skin. After exposure to the UV-B spectrum, 7-dehydrocholesterol is converted to previtamin D\(_3\), which is then transformed to vitamin D\(_3\) by an isomerization process. Vitamin D\(_3\) subsequently undergoes hydroxylation...
tion in the liver by 25-hydroxylase to its major circulating metabolite 25(OH)D3 and then in the kidney by 1α-hydroxylase to its biologically active form 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) (Figure 1). However, recent studies indicate that 1α-hydroxylase is present in many other cells, including lung cells. The exact values that constitute vitamin D deficiency are under debate. It is generally accepted that 25(OH)D3 levels less than 10 to 12 ng/mL represent deficiency, levels less than 20 ng/mL represent insufficiency, and levels greater than 30 ng/mL indicate sufficiency.

Vitamin D is a unique molecule; historically, humans naturally obtain 90% of vitamin D from sunlight exposure and 10% from diet. This has changed because many foods are now fortified with vitamin D, such as milk and milk products, margarine, and breakfast cereals. Vitamin D is not endogenous to most foods, except perhaps fish liver oils (eg, cod liver oil), eggs, and beef liver. Despite fortification of foods, many studies have shown a relative vitamin D insufficiency in westernized society. Binkely et al. conducted a study in a population from Hawaii consisting of 93 adults (30 women and 63 men) with a mean age and body mass index (calculated as weight in kilograms divided by height in meters squared) of 24 years and 23.6, respectively. Their self-reported sun exposure was 28.9 hours per week, yielding a calculated sun exposure index of 11.1. Serum 25(OH)D3 concentration was measured, and a low vitamin D status was defined as less than 30 ng/mL. The mean serum 25(OH)D3 concentration was 31.6 ng/mL. Fifty-one percent of this population had low vitamin D status despite abundant sun exposure.

The true level of vitamin D deficiency in American children and adolescents is unknown, but estimates of 30% to 80% have been reported. In a recent study researchers analyzed data on more than 6,000 children, ages 1 to 21 years, collected by NHANES, 2001-2004. They found that 9% of the study sample, equivalent to 7.6 million children across the United States, was vitamin D deficient (defined as an 25(OH)D3 level <15 ng/mL of blood), whereas another 61%, or 50.8 million, was vitamin D insufficient (15-29 ng/mL). Low vitamin D levels were especially common in children who were older, female, African American, and Mexican American; drank milk less than once a week; or spent more than 4 hours a day watching television, playing videogames, or using computers. Obesity was also noted to be a risk factor for lower serum 25(OH)D3 levels. On the basis of these and other data, it appears that vitamin D deficiency or insufficiency rates in the United States are high.

**GENETICS**

The notion that vitamin D receptor (VDR) polymorphisms could be associated with disease has been suggested previously in immune and inflammatory conditions, such as Crohn disease and tuberculosis. Genome scans for asthma have identified possible linkages on 17 different chromosomes, including chromosome 12, region q13-23. Because the VDR is mapped to chromosome 12q, some geneticists have postulated an association between VDR polymorphisms and ge-

---

Figure 1. Biosynthesis pathway of vitamin D.
netic susceptibility for asthma. A study published in 2004 examined VDR genetic variants in an asthma family-based cohort from Quebec, Canada. They identified 6 variants to be strongly associated with asthma and 4 with atopy. A separate genetic study by Rabj et al also found 4 of 6 VDR variants with significant association to asthma. However, other authors have not found this association. Thus, the possibility of VDR polymorphisms playing a role in the relationship between asthma and vitamin D remains to be clarified.

**VITAMIN D AND AIRWAY EPITHELIUM**

Studies have shown that a number of tissues express 1α-hydroxylase and are able to activate vitamin D. Hansdottir et al demonstrated that lung epithelial cells express high baseline levels of 1α-hydroxylase. This allows airway epithelial cells to convert inactive 25(OH)D3 to the active 1,25(OH)2D3 locally within the lung.

**VITAMIN D AND BRONCHIAL SMOOTH MUSCLE**

Considering the prominent role of bronchial smooth muscle cells in airway remodeling, luminal narrowing, and bronchoconstriction, Bosse et al examined whether the VDR is present. They found that VDR was present in bronchial smooth muscle at both the messenger RNA transcript and protein levels. The functionality of the receptor was then demonstrated by showing a 200-fold change in the expression of the 24-hydroxylase gene after calcitriol (1,25[OH]2D3) stimulation. 24-Hydroxylase regulates vitamin D homeostasis by initiating the degradation of 1,25(OH)2D3. Similarly, Damera and colleagues showed that calcitriol increased expression of 24-hydroxylase on bronchial smooth muscle. They also demonstrated that calcitriol, but not dexamethasone, markedly inhibited platelet-derived growth factor–induced bronchial smooth muscle DNA synthesis in a dose-dependent manner, with a maximum inhibitory effect of 60% (n = 12) at 100nM calcitriol.

A recent study by Banerjee et al also suggested a role for vitamin D in bronchial smooth muscle. Bronchial smooth muscle cells were treated with tumor necrosis factor α (TNF-α) and interferon γ (IFN-γ) for 24 hours in the presence of calcitriol and/or the glucocorticoid fluticasone. In TNF-α-treated cells, calcitriol inhibited RANTES (CCL5) and interferon inducible protein 10 secretion in a concentration-dependent manner. In TNF-α/IFN-γ-treated cells, the combination of both TNF-α and IFN-γ additively inhibited RANTES secretion (by 60%), whereas fluticasone or calcitriol alone inhibited RANTES secretion by only 38% and 20%, respectively.

Song et al investigated the effect of calcitriol on passively sensitized human bronchial smooth muscle cell proliferation and matrix metalloproteinases (MMPs) 9 and 33 (ADAM33) expression. MMPs are believed to play a role in airway remodeling. They found that 1,25(OH)2D3 effectively suppressed passively sensitized bronchial smooth muscle cell proliferation, G1/S transition, in addition to downregulating the expression of MMP-9 and MMP-33 (ADAM33). These data from Bosse et al, Damera et al, Banerjee et al, and Song et al suggest that lower vitamin D levels could lead to bronchial smooth muscle proliferation, cytokine release, and thus airway remodeling. However, Bosse and his group also used microarray technology and real-time polymerase chain reaction to look at gene expression after stimulation with 1,25(OH)2D3. Their results were mixed. For example, they demonstrated that 1,25(OH)2D3 increased the expression of prostaglandin (PG) F synthase (AKR1C3) in bronchial smooth muscle, which is believed to play an important role in the pathogenesis of allergic diseases by regulating the synthesis of PGs, such as PGD2 and PGF2α. PGF synthase in human lung catalyzes the reduction of PGD2 to PGF2α at low pH and the oxidation PGF2α to PGD2 at high pH. PGF2α is a lipid mediator that directs the earliest phases of T-cell recruitment to the airways immediately after exposure to allergens. Furthermore, PGF synthase is known to inactivate cortisol. They also found increased transcription of a Rho guanosine triphosphatase, which can allow the guanosine triphosphate binding protein Rho A to activate its downstream target Rho-kinase, leading to a procontractile state. These data suggest that vitamin D deficiency may be associated with beneficial rather than detrimental effects for asthma. The involvement of Rho A in vitamin D–mediated signal transduction is further supported by data from Khare et al, who investigated the mechanism of phospholipase D activation by vitamin D in Caco-2 cells. Treatment with C3 transferase, which inhibits members of the Rho family of monomeric G proteins, markedly diminished the ability of 1,25(OH)2D3 to stimulate phospholipase D. In addition, Ordóñez-Morán and colleagues established that 1,25(OH)2D3 induces calcium influx and activation of Rho A, which was VDR dependent.

**VITAMIN D AND VASCULAR SMOOTH MUSCLE**

Another important aspect of airway remodeling is angiogenesis. Mitsuhashi et al evaluated whether 1,25(OH)2D3 affects the growth rate of neonatal rat vascular smooth muscle cells. They found that the effect of 1,25(OH)2D3 depends crucially on the context in which it is added. In nonquiescent cells, 1,25(OH)2D3 blunted the growth response to thrombin and platelet-derived growth factor, as well as the induction of c-myc RNA by thrombin. Conversely, in quiescent cells 1,25(OH)2D3 enhanced both the growth response and the induction of c-myc RNA by thrombin.

**IMMUNOMODULATORY EFFECT OF VITAMIN D**

In addition to its role on airway epithelium and bronchial smooth muscle, vitamin D may also be involved in asthma pathogenesis through its effects on the immune system. The discovery of the high-affinity receptor for 1,25(OH)2D3 on monocytes and lymphocytes has also added fuel to this hypothesis. Vitamin D has been shown to have significant immunomodulatory effects by interacting with multiple immune cells involved in asthma, including mast cells, CD4+ T cells of both the Th1 and Th2 phenotype, and monocytes,
Macrophages, dendritic cells (DCs), and regulatory T cells (Tregs). Mast cells play an important role in inflammatory and allergic responses and are one of the main effector cells of the Th2 response. Cross-linking of the high-affinity IgE receptor FceRI by antigens bound to IgE antibodies provides the main immunologic stimulus for mast cell activation. Mast cells have been shown to be increased in the airways of asthmatic patients compared with healthy controls. Baroni et al demonstrated that 1,25(OH)2D3 contributes to the regulation of development and function of mast cells. They found that 1,25(OH)2D3 promotes apoptosis and inhibits maturation of mouse bone marrow–derived mast cell precursors. There was also a dose-dependent inhibition of mast cell differentiation by 1,25(OH)2D3 at various stages of mast cell development. This appeared to be VDR dependent because mast cell progenitors obtained from VDR-ablated mice underwent an accelerated maturation in vitro and gave rise to more responsive mast cells than wild-type mice. They also demonstrated histologically a moderate increase in the number of mast cells in the skin of VDR-deficient mice compared with wild-type mice. On the basis of these data, it is tempting to postulate that vitamin D may play an important inhibitory role in the differentiation, maturation, and homing of mast cells to allergic airways.

Many authors have shown an interaction between vitamin D and CD4+T cells. Reichel et al demonstrated that 1,25(OH)2D3 inhibited synthesis of the Th1 cytokine IFN-γ by phytohemagglutinin-activated human peripheral blood lymphocytes. 1,25(OH)2D3 also inhibited accumulation of IFN-γ messenger RNA in activated peripheral blood lymphocytes in a dose-dependent fashion. The timing of vitamin D exposure (or lack thereof) may have large implications on how immune cells respond to vitamin D. Cord blood cells contain mainly naïve T cells expressing the CD45RA phenotype, which can behave differently from adult peripheral blood T cells. Lee et al found a high correlation between maternal vitamin D levels and cord blood levels in the fetus. Fifty percent of the mothers and 65% of their newborn infants from an inner-city hospital were vitamin D deficient or insufficient, with levels less than 30 ng/mL. Camargo et al analyzed a prospective prebirth cohort study in Massachusetts consisting of 1,194 mother-child pairs. They assessed the maternal intake of vitamin D during pregnancy from a validated food frequency questionnaire. The primary outcome was recurrent wheeze by the age of 3 years. The mean total vitamin D intake during pregnancy was 548 IU/d. By 3 years of age, 186 children (16%) had recurrent wheeze. Compared with mothers in the lowest quartile of daily intake (median, 356 IU), those in the highest quartile (724 IU) had a lower risk of having a child with recurrent wheeze (odds ratio, 0.39; 95% confidence interval, 0.25–0.62). These data are consistent with those of Pichler et al, who evaluated the effects of 1,25(OH)2D3 on human naïve cord blood T lymphocytes and their differentiation into Th1- or Th2-type cells. Their results showed that 1,25(OH)2D3 not only inhibits IL (interleukin) 12–generated IFN-γ production but also suppressed IL-4–induced IL-4 and IL-13 expression. Thus, it appears that 1,25(OH)2D3 inhibits not only Th1 differentiation, as in T cells from adults, but also suppresses Th2 differentiation in cord blood T cells.

Topilski et al investigated the role of vitamin D in the experimental Th2 model of ovalbumin sensitized asthmatic mice. Ovalbumin inhalation induced infiltration of eosinophils (64% vs 0.1% control; P < .001) and lymphocytes (7.7% vs 1.1% control; P = .005) into the bronchoalveolar lavage fluid (BALF) of sensitized mice. However, pretreatment with 1,25(OH)2D3 intraperitoneally significantly inhibited antigen-induced eosinophil recruitment into the BALF (64% ovalbumin vs 9.8% vitamin D3 and ovalbumin, P < .001). In addition, IL-4 levels in BALF derived from 1,25(OH)2D3-treated mice were reduced compared with the ovalbumin alone (33 pg/mL of ovalbumin vs 8 pg/mL of vitamin D and ovalbumin, P = .007). This trend toward inhibition was maintained even when 1,25(OH)2D3 was injected 2 weeks after mice were sensitized with ovalbumin. These findings suggest that 1,25(OH)2D3 significantly reduces the airway inflammatory response and IL-4 levels in BALF when given at the initiation of sensitization or after the CD4+ population was already skewed towards the Th2 population. Topilski et al also found that 1,25(OH)2D3 inhibits chemotaxis and actin polymerization by CD4+ T cells, suggesting that in addition to its role in cytokine production it also may be involved in homing of T cells to lymph nodes or tissues.

Matheu et al used a similar murine model of pulmonary eosinophilia with ovalbumin sensitized mice to evaluate the effects of vitamin D on a Th2 profile. Five-week-old mice were primed on day 0 with ovalbumin intraperitoneally. Then they were nasally challenged with ovalbumin on days 7, 8, 9, 10, and 11. Some mice received subcutaneous injections of vitamin D. Their experiments yielded mixed results. Although treatment with vitamin D augmented allergen-induced Th2 cytokines (IL-4 and IL-13) and IgE production, the local inflammatory response in BALF was significantly decreased with impaired recruitment of eosinophils and lower levels of IL-5. Matheu et al attributed these findings to late treatment with vitamin D after establishment of an early immune response. However, as noted herein, Topilski et al showed that inhibition of eosinophilic recruitment was maintained even when 1,25(OH)2D3 was injected 2 weeks after mice were ovalbumin sensitized. Despite these differing results, both Topilsky et al and Matheu et al found that vitamin D decreased the levels of eosinophils and Th2 cytokines in BALF of ovalbumin sensitized mice. However, seemingly contradictory evidence to these findings comes from VDR knockout mice that failed to develop airway inflammation, eosinophilia, or airway hyperresponsiveness after ovalbumin sensitization.

Boonstra et al evaluated the effects of vitamin D on an in vitro model from mice transgenic for an ovalbumin-specific α/β T-cell receptor. They cultured these cells with splenic...
antigen-presenting cells and ovalbumin peptide with medium alone or medium supplemented with 1,25(OH)2D3. Cytokine production was determined by flow cytometry on restimulation. As in other models described herein, the Tp1 cells showed a reduction in the number of IFN-γ–producing cells. However, similar to Mathieu et al, they also noted an increased frequency of IL-4–producing cells. The vitamin D–induced effects were thought to be largely mediated via IL-4 because neutralization of IL-4 with a monoclonal antibody almost completely abrogated Tp1 cell development. In addition, the increased production of Tp2 cytokines correlated with increased expression of the Tp2-specific transcription factor GATA-3.

When we examine all the data on vitamin D using the experimental murine model for asthma, it appears as though vitamin D decreases the peripheral blood Tp1 profile and increases the Tp2 profile. Seemingly contradictory to this Tp1-Tp2 skewing is the reduced local inflammatory response seen in the murine lung in vitamin D–treated mice. In particular, the BALF has consistently been shown to have decreased eosinophils and Tp2 cytokines. The question that is raised is why do ovalbumin sensitized mice treated with vitamin D have decreased airway inflammation when VDR knockout mice also do not develop airway inflammation on ovalbumin exposure. One possibility is that knocking out the VDR in all tissues can alter the homeostasis of calcium and have widespread effects on not only immune cells but also all cells of the body, especially because the VDR is expressed in many tissues and cells. This also underlies the inherent limitations of using murine models for explaining human disease and does not take into consideration the timing of exposure of vitamin D or the effects of Tregs to this model.

Antigen-presenting cells, such as DCs, express the VDR and are key targets of VDR agonists. Hewison et al32 and his group demonstrated that monocyte-derived DCs are able to synthesize 1,25(OH)2D3 in vitro as a consequence of increased 1α-hydroxylase expression Numerous studies have demonstrated that 1,25(OH)2D3 and its analogs inhibit the differentiation and maturation of DCs.47–51 These studies have shown that in vitro treatment of DCs with 1,25(OH)2D3 and its analogs leads to downregulated expression of the costimulatory molecules CD40 and CD80/CD86 and to decreased IL-12 and enhanced IL-10 production, resulting in decreased T-cell activation. The block of maturation, coupled with abrogation of IL-12 and strongly enhanced production of IL-10, may explain the capacity of VDR agonists to induce DCs with tolerogenic properties that favor regulatory T-cell enhancement.

Vitamin D has been shown to promote the induction of Treg cells.37,38,41–43 IL-10–secreting Tregs are of particular importance. IL-10 is a potent antiinflammatory cytokine and inhibits Tp1 and Tp2 immune responses, which has led to considerable interest in its role in allergic inflammation. Convincing experiments for this interaction comes from Xystrakis et al.36 and Urry et al.39 They showed that human CD4+ Tregs secrete higher levels of IL-10 when stimulated in the presence of dexamethasone and vitamin D.36 Furthermore, after stimulation by allergen, IL-10–secreting Tregs inhibited cytokine secretion by allergen-specific Tp2 cells in an IL-10–dependent manner. Xystrakis et al also looked at glucocorticoid-resistant asthma. They cultured CD4+ T cells from patients with glucocorticoid-resistant asthma and found that dexamethasone did not enhance secretion of IL-10. The addition of vitamin D3 with dexamethasone to cultures of these CD4+ T cells enhanced IL-10 synthesis to levels observed in cells from glucocorticoid-sensitive patients cultured with dexamethasone alone.39 The role of vitamin D in IL-10 synthesis is supported by findings that vitamin D can also increase the expression of IL-10 by DCs. Taher et al32 investigated whether the combination of allergen immunotherapy with 1,25(OH)2D3 in mice can potentiate the suppressive effects of immunotherapy and whether IL-10 and TGF-β are involved. Interestingly, when compared with immunotherapy alone, coadministration of 10 ng of 1,25(OH)2D3 with 100 µg of ovalbumin immunotherapy significantly inhibited airway hyperresponsiveness and decreased serum ovalbumin–specific IgE levels, airway eosinophilia, and Tp2-related cytokines. This correlated with increased IL-10 and TGF-β levels in lung tissues. The suppressive effect of this combined immunotherapy was completely inhibited by treatment with monoclonal antibodies to IL-10 receptor and TGF-β.

VITAMIN D AND RESPIRATORY INFECTIONS

Respiratory viral infections are important initiators of asthma exacerbations. Recent data suggest that vitamin D reduces the risk of respiratory viral infections. In a randomized controlled trial conducted with postmenopausal African American women living in Long Island, New York, those taking 800 IU/d of vitamin D had a 60% reduction in the incidence of seasonal influenza or common cold. However, those taking 2,000 IU/d had a 90% reduction.53 On the basis of these and other studies, it was suggested that differences in skin pigmentation and, thus, vitamin D production explained the variations in risk of childhood respiratory infections in Hawaii.54 Additional support for the role of vitamin D is provided by data showing that it is capable of inducing the expression of several anti-infective molecules, such as cathelicidin. Thus, deficiency of vitamin D might lead to greater occurrences of respiratory tract infections, and consequently, more asthma exacerbations.

CONCLUSIONS

One critical issue in assessing the role of vitamin D in asthma is that there is no uniform agreement on what constitutes vitamin D sufficiency, insufficiency, and deficiency. It is generally accepted that serum 25(OH)D3 levels less than 10 to 12 ng/mL represent deficiency, levels less than 20 ng/mL represent insufficiency, and levels greater than 30 ng/mL represent sufficiency. However, a review of existing studies shows associations between airway diseases and serum 25(OH)D3 using only a single
measurement. This can result in unreliable data because serum 25(OH)D3 levels usually increase by 5 to 10 ng/mL between winter and summer (Christopher Gallagher, MD, unpublished data, September 2009). For example, an individual may be vitamin D deficient in April but vitamin D sufficient in June because of sun exposure. Thus, in conducting studies examining the relationship between serum 25(OH)D3 levels and asthma, more frequent measurements of serum 25(OH)D3 should be performed to adjust for the seasonal variation. More importantly, there are no data defining what constitutes appropriate levels of vitamin D in target organs, such as lung. Dose-response data on the effects of vitamin D in raising levels in the serum and treating diseases such as asthma are clearly needed to best define the role of vitamin D in asthma.

Studies such as the NHANES trial suggest an association between vitamin D deficiency and asthma. However, these studies suffer from lack of long-term follow-up of patients, and only a single measurement of serum 25(OH)D3 was obtained, which was uncorrected for season. Further studies are needed to investigate the relationship between vitamin D levels and parameters for atopy and asthma using frequent blood sampling.

We hypothesize that vitamin D supplementation will lead to better asthma control by inhibiting the influx of inflammatory cytokines in the lung and increasing the secretion of IL-10 by CD4+CD25+Foxp3+ Treg cells and DCs, while concurrently inhibiting DC activation and maturation. This block of maturation, coupled with enhanced production of IL-10, may explain the capacity of VDR agonists to induce
DCs with tolerogenic properties that favor Treg enhancement (Figure 2). Furthermore, early vitamin D supplementation to the mother and neonate may be paramount in terms of its effect on the development of a T<sub>reg</sub> or T<sub>17</sub> phenotype in the child. Proof of this hypothesis requires carefully designed long-term interventional trials with vitamin D in patients with asthma.

REFERENCES